Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.
Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N. Kaira K, et al. Among authors: sunaga n. Lung Cancer. 2013 Oct;82(1):103-8. doi: 10.1016/j.lungcan.2013.07.008. Epub 2013 Aug 5. Lung Cancer. 2013. PMID: 23927884 Clinical Trial.
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Masuda T, et al. Among authors: sunaga n. Clin Transl Oncol. 2015 Sep;17(9):702-9. doi: 10.1007/s12094-015-1297-8. Epub 2015 May 20. Clin Transl Oncol. 2015. PMID: 25990507
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T, Imai H, Masuda T, Miura Y, Seki K, Yoshino R, Kaira K, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Kuwako T, et al. Among authors: sunaga n. Cancer Chemother Pharmacol. 2015 Oct;76(4):761-9. doi: 10.1007/s00280-015-2841-5. Epub 2015 Aug 8. Cancer Chemother Pharmacol. 2015. PMID: 26254024
Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case.
Imai H, Matsumura N, Yamazaki Y, Kanayama Y, Masuda T, Kuwako T, Kamide Y, Tomizawa T, Matsumoto S, Mitsui T, Kaira K, Ono A, Koga Y, Shibusawa N, Sunaga N, Hisada T, Yokoo H, Yamada M. Imai H, et al. Among authors: sunaga n. Intern Med. 2015;54(24):3171-6. doi: 10.2169/internalmedicine.54.5069. Epub 2015 Dec 15. Intern Med. 2015. PMID: 26666606 Free article.
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T. Kaira K, et al. Among authors: sunaga n. Cancer Chemother Pharmacol. 2017 Jan;79(1):165-171. doi: 10.1007/s00280-016-3217-1. Epub 2016 Dec 19. Cancer Chemother Pharmacol. 2017. PMID: 27995307 Clinical Trial.
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Imai H, et al. Among authors: sunaga n. Cancer Chemother Pharmacol. 2017 Mar;79(3):497-505. doi: 10.1007/s00280-016-3232-2. Epub 2017 Feb 6. Cancer Chemother Pharmacol. 2017. PMID: 28168310 Free PMC article.
171 results